Vancouver, Canada, July 12, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces its participation in the upcoming Psychedelic Medicine – Israel 2024 conference. This event will take place in Tel Aviv, Israel from July 28th to 30th, bringing together leading experts and researchers from around the world in the field of psychedelic medicine.
Clearmind’s CEO, Adi Zullof-Shani, Ph.D., will present a compelling talk titled “5-Methoxy-2-Aminoindane (MEAI) as a Binge Behavior Regulator.” This presentation is scheduled for Monday, July 29th, in the Research Presentations 1 session, from 9:00 a.m. to 10:40 a.m. IDT. Dr. Zullof-Shani will provide insights into MEAI’s potential to regulate binge behaviors, highlighting its innovative application in treating addiction-related disorders.
Additionally, esteemed researchers Prof. Joseph Tam and Dr. Saja Baraghithy from the Obesity and Metabolism Laboratory in The Hebrew University of Jerusalem, will present their abstract titled “5-methoxy-2-aminoindane (MEAI), a mild psychedelic agent, attenuates diet-induced obesity.” This presentation is scheduled for Tuesday, July 30th, in the Research Presentations 3 session, from 2:00 p.m. to 4:05 p.m. IDT. Their presentation will delve into the promising results of MEAI in attenuating obesity and its related metabolic complications, showcasing its potential as a therapeutic agent in obesity management.
About the Presentations:
5-Methoxy-2-Aminoindane (MEAI) as a Binge Behavior Regulator
Dr. Zullof-Shani will discuss the unique properties of MEAI, a psychoactive aminoindane derivative. MEAI has shown promise in reducing the desire to consume alcoholic beverages while inducing a euphoric, alcohol-like slightly tipsy but controlled experience. This presentation will explore MEAI’s potential as a regulator of binge behaviors, providing a novel approach to addiction treatment.
5-methoxy-2-Aminoindane (MEAI), a Mild Psychedelic Agent, Attenuates Diet-induced Obesity
Dr. Baraghithy will present her research findings on the weight loss effects of MEAI. The study demonstrated that MEAI significantly reduces overweight and adiposity in a diet-induced obesity (DIO) mouse model. The researchers will share compelling evidence that MEAI reduces fat mass, preserves lean mass, improves glucose metabolism, reduces hepatic steatosis, and increases energy expenditure, making it a promising therapeutic candidate for obesity management.
Dr. Zullof-Shani, CEO of Clearmind Medicine, commented, “We are honored to present our groundbreaking research at the Psychedelic Medicine – Israel 2024 conference. MEAI has shown remarkable potential in regulating several binge behaviors and treating overweight, and we are excited to share these findings with the scientific community. Our commitment to pioneering research in psychedelic-derived therapeutics continues to drive us forward as we seek to address major health challenges.”
Psychedelic Medicine – Israel 2024 will provide an interdisciplinary international forum for exchanging ideas, unveiling innovations and training in the basics of psychedelic assisted psychotherapy. The conference will encompass basic, translational and clinical research. A richly varied program will include Plenary Lectures, Thematic Symposia, Poster Sessions, Workshops and informal Salons for discussion and interaction.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of eighteen patent families including 28 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”